Johnson & Johnson (JNJ) Stake Lessened by Independent Investors Inc.

Independent Investors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 88,333 shares of the company’s stock after selling 8,500 shares during the quarter. Johnson & Johnson comprises 5.1% of Independent Investors Inc.’s investment portfolio, making the stock its 2nd largest position. Independent Investors Inc.’s holdings in Johnson & Johnson were worth $11,685,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. State Street Corp boosted its position in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. Harbour Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 13,327.8% during the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the last quarter. Korea Investment CORP boosted its position in shares of Johnson & Johnson by 38.9% during the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares during the last quarter. Bank of Nova Scotia boosted its position in shares of Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in Johnson & Johnson in the 1st quarter worth approximately $65,598,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Lessened by Independent Investors Inc.” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/10/johnson-johnson-jnj-stake-lessened-by-independent-investors-inc.html.

Johnson & Johnson (JNJ) opened at $140.35 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The stock has a market capitalization of $379,659.03, a P/E ratio of 19.79, a PEG ratio of 2.87 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.39%. Johnson & Johnson’s payout ratio is 58.33%.

A number of analysts recently weighed in on JNJ shares. UBS AG restated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $143.70.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply